Skip to main content
main-content

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Editors' pick

10-24-2018 | Diabetes distress | Editorial | Article

Feeling stressed out and not meeting goals: A vicious cycle impacting diabetes self-management

Clinical psychologists Diana Naranjo and Korey Hood tackle the negative feedback loops that can develop around diabetes self-management and offer their insights on strategies to identify and address the roots of distress.

11-10-2018 | Dapagliflozin | Highlight | News

DECLARE-TIMI 58 supports CV benefits of SGLT2 inhibitor class

The results of the DECLARE-TIMI 58 trial show a broadly positive effect of dapagliflozin on cardiovascular outcomes, especially heart failure, in patients with type 2 diabetes.

11-10-2018 | Dapagliflozin | Feature | Video

Expert commentary: DECLARE-TIMI 58

Miles Fisher talks to medwireNews about the results of the dapagliflozin cardiovascular outcomes trial DECLARE-TIMI 58.

Latest from across the site

11-12-2018 | SGLT2 inhibitors | News

Meta-analysis supports cardioprotective benefits of SGLT2 inhibitors

Sodium-glucose cotransporter 2 inhibitors reduce the risk for heart failure hospitalization and renal disease progression in patients with type 2 diabetes regardless of existing cardiovascular disease, meta-analysis data show.

Source:

Lancet 2018; doi:10.1016/S0140-6736(18)32590-X
Lancet 2018; doi:10.1016/S0140-6736(18)32824-1

11-10-2018 | Dapagliflozin | Highlight | News

DECLARE-TIMI 58 supports CV benefits of SGLT2 inhibitor class

The results of the DECLARE-TIMI 58 trial show a broadly positive effect of dapagliflozin on cardiovascular outcomes, especially heart failure, in patients with type 2 diabetes.

Source:

N Engl J Med 2018; doi:10.1056/NEJMoa1812389

11-10-2018 | Retinopathy | Article

Diabetic retinopathy grade as a predictive marker of severity of cardiovascular disease and mortality: DIVERSE Study Group

Shah K et al. Int J Diabetes Dev Ctries 2018. doi: 10.1007/s13410-018-0699-x

11-09-2018 | Adolescents | News

Elevated multiple complication risk in youth with type 1 diabetes

Patients with type 1 diabetes may develop multiple complications even before they reach adulthood, shows an analysis of the SEARCH for Diabetes in Youth Study.

Source:

Lancet Child Adolesc Health 2018; doi:10.1016/S2352-4642(18)30309-2
Lancet Child Adolesc Health 2018; doi:10.1016/S2352-4642(18)30337-7

11-08-2018 | Nephropathy | News

Novel VAP-1 inhibitor shows promise for diabetic kidney disease

The novel, orally active vascular adhesion protein-1 inhibitor ASP8232 effectively reduces albuminuria, with few side effects, in patients with type 2 diabetes and chronic kidney disease, phase II study data show.

Source:

Lancet Diabetes Endocrinol 2018; doi:10.1016/ S2213-8587(18)30289-4
Lancet Diabetes Endocrinol 2018; doi:10.1016/ S2213-8587(18)30304-8

11-08-2018 | Cardiovascular disorders | Review | Article

The evolving role of the cardiologist in the management of type 2 diabetes

Chilton RJ et al. Curr Diab Rep 2018; 18: 144. doi: 10.1007/s11892-018-1114-1

medwireNews@EASD2018

The 2018 EASD Annual Meeting took place in Berlin from the 1st to 5th October. Click here for news and expert commentary, including the EASE, PREVIEW, and HARMONY trials.

Latest from us on Twitter

Most read articles

Meet our Editorial Board

New Content Item Meet our Advisory Board

image credits